Arcturus Therapeutics’ Post

An important step towards strengthening development and manufacturing of mRNA vaccines in Japan.

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Hepatitis B Virus (#HBV) peptides. Hepatitis C can often be treated successfully by taking medicines for several weeks. If the infection is diagnosed in the early stages, known as acute hepatitis, treatment may not need to begin straight away. Instead, you may have another blood test after a few months to see if your body fights off the virus. If the infection continues for several months, known as chronic hepatitis, treatment will usually be recommended. Hepatitis C medicines! Hepatitis C is treated using direct-acting antiviral (DAA) tablets. DAA tablets are the safest and most effective medicines for treating hepatitis C. They're highly effective at clearing the infection in more than 90% of people. The tablets are taken for 8 to 12 weeks. The length of treatment will depend on which type of hepatitis C you have. 📝 Some types of hepatitis C can be treated using more than 1 type of DAA. #NHS/ #WHO-approved #hepatitis C medicines include: — sofosbuvir — a combination of #ledipasvir and sofosbuvir — a combination of #ombitasvir, paritaprevir and ritonavir, taken with or without dasabuvir — a combination of #elbasvir and grazoprevir — a combination of #sofosbuvir and velpatasvir — a combination of sofosbuvir, #velpatasvir and #voxilaprevir — a combination of #glecaprevir and #pibrentasvir — #ribavirin Join us on our journey!🌐 #TajPharma 📧: info@tajpharma.com📍

GeoVax $GOVX; Achieves Milestone in Transition to Commercially Validated Manufacturing System #finance #stocks #marketing #stockmarket #pharma #pharmaceutical #biotech #biotechnology https://hubs.ly/Q02nmWgY0

IDT and Sanofi to manufacture mRNA vaccines under development Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials targeting a number of medical conditions. The facility is one of only a few such facilities in the Asia Pacific region. mRNA technology came to the fore during the Covid-19 pandemic with vaccines developed quickly using the new technology proving effective in protecting the public from disease. The value of initial services being provided by IDT is up to $3.5 million, with the agreement allowing for follow on work packages. #vaccines #pharmaceuticals #manufacturing #manufacturingnews #mRNA @sanofi @IDTAus Sanofi IDT Australia Limited Moderna https://lnkd.in/geiXiass

Lipid Nanoparticle overview for those in the first quarter of their Biotech career. Partner with Microfluidics now to support your success through every quarter of your career cycle!

In May, the online discussions among healthcare professionals (HCPs) regarding pharmaceutical companies primarily revolved around three key topics: 1. An app created by Abbott to assess the risk of death or hospitalisation in patients with heart failure. 2. AstraZeneca's decision to withdraw its COVID-19 vaccine. 3. A second fire occurring at the Novo Nordisk headquarters in Denmark. For detailed insights into the sentiments expressed concerning these events, please refer to the full tracker. https://lnkd.in/emHBAFjs #pharma #healthcare #COVID19

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalSplenomegalyTherapeuticsMarket #PharmaceuticalIndustry #SplenomegalyTreatment #DrugTherapy #Vaccination #SurgicalInterventions #HealthcareSector #PatientOutcomes #QualityOfLife #MarketGrowth

NanoViricides, Inc. spotlights lead drug candidate's potential as COVID therapy By Emily Jarvie NanoViricides, Inc. (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies of NV-387 have shown it can be “highly effective” in treating COVID infections. In one study, intravenous injection of NV-387 led to a 180% improvement in survival compared to just a 50% improvement for anti-coronavirus drug Remdesivir. NV-387 in two oral formulations, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, was also evaluated in a Phase 1 human clinical trial. No subjects dropped out of the trial or reported adverse events, indicating NV-387’s safety and tolerability even at high dosage levels. NanoViricides (NYSE-A:NNVC) said there is a clear need for a "highly effective and preferably oral drug" against COVID, which has become a biannual affair with new variants leading each wave in the US. "President Joe Biden has thankfully recovered from the bout of COVID caused by a new variant," NanoViricides CEO Dr Anil Diwan commented. "This again brings into limelight the lack of strong drugs against COVID; a gap that NV-387 is expected to fulfill." Further, NanoViricides has found that its lead drug candidate has a very wide antiviral spectrum, also covering RSV, influenza, and poxviruses. The company is currently seeking strategic partnerships with pharmaceutical companies to advance NV-387 toward regulatory approvals for multiple antiviral indications. Larry Cole - my usual disclaimers are in play here, I was not asked to post this, nor do I know anyone who is directly involved with this announcement or firm. This is a publoic service announcment about what is potentially in the pipeline for Covid therapy.

𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 4.0% 𝗖𝗔𝗚𝗥 𝗳𝗿𝗼𝗺 2024 𝘁𝗼 2029 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁-https://lnkd.in/gzqjFKmP The size of global vaccines market (including COVID-19 vaccines) in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029. Similarly The global vaccines market (excluding COVID-19 vaccines) in terms of revenue was estimated to be worth $53.0 billion in 2024 and is poised to reach $80.3 billion by 2029, growing at a CAGR of 8.7% from 2024 to 2029. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 ChemGenes TransCode Therapeutics, Inc. OPKO Diagnostics, LLC  Floridian Clinical Research GenVec Harrisvaccines PanAmerican Clinical Research     Medicine Center Pharmacy Synterex VaxServe LATINABA FARRAR Primrose Bio Ventavia Research Group GlobeImmune, Inc. Nanotherapeutics, Inc. DP Clinical Inc. FFF Enterprises, Inc. Bridge Laboratories Epitopea Eurofins Viracor BioPharma Services Bionique Testing Laboratories Aegis Life, Inc. BioTechLogic, Inc. Ligandal PlantForm Corporation Isolere Bio By Donaldson The Quantic Group, Pharmaceutical Consultants    GlycoNet United Biomedical, Inc. (UBI) INTERNATIONAL SERUM INDUSTRY ASSOCIATION SciSafe Inc. PendoTECH Jurata Thin Film BE Pharmaceuticals, Inc. Reliance Wholesale Inc.  Probity Medical Research Inc. (PMR) Aaron Diamond AIDS Research Center NEOMED-LABS Micron Biomedical, Inc.

𝐂𝐚𝐧 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐢𝐭𝐬 𝐠𝐫𝐨𝐰𝐭𝐡 𝐚𝐧𝐝 𝐫𝐞𝐚𝐜𝐡 $94.9 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 𝐑𝐄𝐐𝐔𝐄𝐒𝐓 𝐅𝐑𝐄𝐄 𝐒𝐀𝐌𝐏𝐋𝐄 𝐑𝐄𝐏𝐎𝐑𝐓-https://lnkd.in/dQxjBXMx The size of global vaccines market (including COVID-19 vaccines) in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029. Similarly The global vaccines market (excluding COVID-19 vaccines) in terms of revenue was estimated to be worth $53.0 billion in 2024 and is poised to reach $80.3 billion by 2029, growing at a CAGR of 8.7% from 2024 to 2029 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 GSK plc (UK), Merck & Co Inc (US), Pfizer Inc (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson and Johnson Services, Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt Ltd (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited. (Japan), Panacea Biotec (India), Biological E Ltd. (India), etc 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Vaccines Europe MEVAC for Vaccines CZ Vaccines VBI Vaccines Inc.      AJ Vaccines WuXi Vaccines Bharat Serums and Vaccines Limited      Sanofi FDA PRA Health Sciences      The Janssen Pharmaceutical Companies of Johnson & Johnson PATH GSK MedImmune MSD Zoetis Takeda Novartis  Wockhardt Ltd. Merial Zydus Group Chiltern US Pharmacopeia   Amyris Phibro Animal Health Resilience Agenus BioProcess International Curative One Health Trust      INOVIO Pharmaceuticals, Inc.    Velocity Clinical Research, Inc. Personalis, Inc. Dynavax Technologies  ImmunityBio, Inc.